Evidence map›Paper›PMID 25740255›Full record

ArticleNature communications2015

Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

Mohammed Eslam, Ahmed M Hashem, Reynold Leung, Manuel Romero-Gomez, Thomas Berg, Gregory J Dore, Henry L K Chan, William L Irving, David Sheridan, Maria L Abate and 20 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 3 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 3 syntheses or guidelines pooled it, 173 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Role ofResearch square · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Interferon lambda 4 is a gut antimicrobial protein.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. The Association ofInternational journal of molecular sciences · 2024
    Article
  17. Review
  18. Review
  19. Review
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 8 countries.

Mohammed EslamStorr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, New South Wales 2145, Australia.
Ahmed M HashemFaculty of Engineering, Department of Systems and Biomedical Engineering, Minia University, Minia 6111, Egypt.
Reynold Leung1] Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, New South Wales 2145, Australia [2] Institute of Immunology and Allergy Research, Westmead Hospital and Westmead Millennium Institute, University of Sydney, Sydney, New South Wales 2145, Australia.
Manuel Romero-GomezUnit for The Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla 41014, Spain.
Thomas Berg1] Medizinische Klinik m.S. Hepatologie und Gastroenterologie, Charite, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin 04103, Germany [2] Department of Hepatology, Clinic for Gastroenterology and Rheumatology, University Clinic Leipzig, Leipzig 04103, Germany.
Gregory J Dore1] Kirby Institute, The University of New South Wales, Sydney, New South Wales 2052, Australia [2] St Vincent's Hospital, Sydney, New South Wales 2052, Australia.
Henry L K ChanDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
William L IrvingNIHR Biomedical Research Unit in Gastroenterology and the Liver, University of Nottingham, Nottingham NG7 2UH, UK.
David Sheridan1] Liver Research Group, Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK [2] Institute of Translational and Stratified Medicine, Plymouth University, Plymouth PL4 8AA, UK.
Maria L AbateDivision of Gastroenterology and Hepatology, Department of Medical Science, University of Turin, Turin 10126, Italy.
Leon A AdamsSchool of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, University of Western Australia, Nedlands, Western Australia 6009, Australia.
Alessandra MangiaDivision of Hepatology, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo 71013, Italy.
Martin WeltmanDepartment of Gastroenterology and Hepatology, Nepean Hospital, Sydney, New South Wales 2747, Australia.
Elisabetta BugianesiDivision of Gastroenterology and Hepatology, Department of Medical Science, University of Turin, Turin 10126, Italy.
Ulrich SpenglerDepartment of Internal Medicine I, University of Bonn, Bonn 53105, Germany.
Olfat ShakerFaculty of Medicine, Medical Biochemistry and Molecular Biology Department, Cairo University, Cairo 11562, Egypt.
Janett FischerMedizinische Klinik m.S. Hepatologie und Gastroenterologie, Charite, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin 04103, Germany.
Lindsay MollisonDepartment of Gastroenterology and Hepatology, Fremantle Hospital, Fremantle, Western Australia 6160, Australia.
Wendy ChengDepartment of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia 6000, Australia.
Elizabeth Powell1] Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia [2] The University of Queensland, School of Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland 4072, Australia.
Jacob NattermannDepartment of Internal Medicine I, University of Bonn, Bonn 53105, Germany.
Stephen RiordanGastrointestinal and Liver Unit, Prince of Wales Hospital and University of New South Wales, Sydney, New South Wales 2031, Australia.
Duncan McLeodDepartment of Anatomical Pathology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Sydney, New South Wales 2145, Australia.
Nicola J ArmstrongSchool of Mathematics and Statistics, University of Sydney, Sydney, New South Wales 2006, Australia.
Mark W DouglasStorr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, New South Wales 2145, Australia.
Christopher LiddleStorr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, New South Wales 2145, Australia.
David R BoothInstitute of Immunology and Allergy Research, Westmead Hospital and Westmead Millennium Institute, University of Sydney, Sydney, New South Wales 2145, Australia.
Jacob GeorgeStorr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, New South Wales 2145, Australia.
Golo AhlenstielStorr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, New South Wales 2145, Australia.
International Hepatitis C Genetics Consortium (IHCGC)
The University of Sydney · AUUNSW Sydney · AUUniversity of Turin · ITUniversity of Bonn · DEWestmead Hospital · AUWestmead Institute · AUCharité - Universitätsmedizin Berlin · DEIstituti di Ricovero e Cura a Carattere Scientifico · ITNepean Hospital · AUNewcastle University · GBPrince of Wales Hospital · CNPrincess Alexandra Hospital · AUCairo University · EGCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESFremantle Hospital · AUHospital Universitario de Valme · ESMinia University · EGRoyal Perth Hospital · AUSir Charles Gairdner Hospital · AUUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tissue fibrosis is a core pathologic process that contributes to mortality in ~45% of the population and is likely to be influenced by the host genetic architecture. Here we demonstrate, using liver disease as a model, that a single-nucleotide polymorphism (rs12979860) in the intronic region of interferon-λ4 (IFNL4) is a strong predictor of fibrosis in an aetiology-independent manner. In a cohort of 4,172 patients, including 3,129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B (CHB) and 488 with non-alcoholic fatty liver disease (NAFLD), those with rs12979860CC have greater hepatic inflammation and fibrosis. In CHC, those with rs12979860CC also have greater stage-constant and stage-specific fibrosis progression rates (P<0.0001 for all). The impact of rs12979860 genotypes on fibrosis is maximal in young females, especially those with HCV genotype 3. These findings establish rs12979860 genotype as a strong aetiology-independent predictor of tissue inflammation and fibrosis.

Indexed as

Cohort StudiesFemaleGenotypeHepatitis, ChronicHumansInterferon LambdaInterleukinsLiverLiver CirrhosisLogistic ModelsNon-alcoholic Fatty Liver DiseasePolymorphism, Single NucleotideSex FactorsStatistics, NonparametricIFNL4 protein, humanInterferon LambdaInterleukins

Identifiers

PMID25740255
PMCPMC4366528
OpenAlexW2047615185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.